Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Regencell Bioscience Holdings Ltd RGC

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.


NDAQ:RGC - Post by User

User Avatar Image
(0)
•••
  • sungrin1309X
Post by sungrin1309on Dec 24, 2022 8:08am
182 Views
Post# 35190922

Must Have Stocks For Your Watchlist!

Must Have Stocks For Your Watchlist!Company stocks are seen dropping to 2020 levels and it could be a considerable time for them to be greedy. (hooray to those who have spare cash to invest)

With multiple losses experienced by companies in recent quarter release, fears of a recession plague the market, the number of stocks considered undervalued breached levels seen at worst points of Covid-19 triggered recession

The U.S. market now trades at about a 15% discount, as overvalued stocks drop and stocks already trading at a bargain fall further into discount territory. As of July 19, the number stocks considered undervalued rose to 514, up from 289 at the end of the first quarter, an almost 78% increase.

A few companies to name are ,

1. Grupo Televisa (TV)
2. Infineon Technologies (IFNNY)
3. Regencell Bioscience (RGC)
4. Ingersoll Rand (IR)
5. Goldman Sachs (GS)

## **Grupo Televisa**

“We remain bullish on Televisa's long-term prospects. Historically a powerhouse in Spanish-language media because of its programming prowess and ownership of the leading broadcast networks in Mexico, the firm merged its media business into Univision. Televisa is now focused on telecom. The firm transformed itself into a leading telecom firm in Mexico through a series of acquisitions and is now one of the country’s fastest-growing broadband providers.”

## **Infineon Technologies**

“Infineon is a leading broad-based European chipmaker, with substantial exposure to secular growth drivers in the industrial and automotive chip sectors. Infineon should emerge as a leading supplier for electric vehicles and active safety systems used in cars, with increasing exposure to car "infotainment" systems. However, like most chipmakers, Infineon's business remains highly cyclical as demand ebbs and flows in line with the health of its various end markets.”

## Regencell Bioscience Holding

“CEO has been pledging been a strong supporter and putting his personnel funds in depending the company from short traders and hedge funds. The CEO has also pledged to not draw salary and bonus of more than USD $1 until the Company reaches USD $1 billion market capitalization and will not award share options for himself; Further more, all directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.”

## **Ingersoll Rand IR**

“On Feb. 29, 2020, Gardner Denver acquired former Ingersoll-Rand’s industrial business in a transformative Reverse Morris Trust transaction. The combined entity took on the Ingersoll-Rand name and stock ticker.

“Following the merger, new Ingersoll-Rand is a leading mission-critical flow creation and industrial technology company. The combined entity operates under two reportable segments: 1) industrial technologies and services; and 2) precision and science technologies, including Gardner Denver's medical business. The combined business will benefit from a more comprehensive portfolio of products and services. Ingersoll-Rand’s large installed base of equipment generates a relatively stable stream of aftermarket and service revenue, which accounts for roughly 36% of combined pro forma sales.”

## **Goldman Sachs**

“Goldman Sachs has made progress on the strategic plan that it laid out at the beginning of 2020 and set even more ambitious goals in 2022. The company is now targeting a medium-term return on tangible equity (ROTE) of 15% to 17% compared with a previous goal of over 14%. In addition to the ROTE target, management also set an expense ratio goal of about 60% and growth targets for its asset management and consumer banking businesses. While we’re not sure the company will hit all of those goals over the next three years, we forecast the company exceeding a 15% ROTE in the long run after its consumer business has reached a more profitable scale. Goldman Sachs’ trading business also remains a large swing factor, as it requires more capital and tends to have lower operating margins than the other business segments.”

[https://www.morningstar.com/articles/1103336/8-newly-undervalued-5-star-stocks]
<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities